News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
We now rank 3rd in pharmaceutical production by volume and 14th by value
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Subscribe To Our Newsletter & Stay Updated
